Mesoblast enrolls patients in end-stage heart failure therapy trial

Company News

by Jessica Amir

Mesoblast (ASX:MSB) has enrolled 159-patients into its clinical trial for cell therapy on end-stage heart failure patients.

The regenerative medicine company’s trial involves its novel allogeneic MPC therapy (mesenchymal precursor cell (MPC)) on heart failure patients, who need left ventricular assistant devices.

The trial is funded by the United States National Institute of Health and the Canadian Institute of Health Research.

Currently about there is about 50,000 end-stage heart failure patients in the US and there’s a 50 per cent chance (with maximum therapy) of surviving one year. 

Mesoblast says its therapy should have a substantial positive impact on patients.

Shares in Mesoblast (ASX:MSB) are trading 0.36 per cent higher to $1.38.

 

Jessica Amir

Finance News Network
Jessica joined FNN in January 2017 after having worked in financial advising for seven years and in TV journalism for seven years, specialising in finance, equities and analysis. She has interviewed former Prime Ministers of Australia, Tony Abbott, Julia Gillard and Kevin Rudd and ex Treasurer Jo Hockey. Jessica has worked as a journalist with Sky News Business, ABC 1, ABC's The Business, ABC24 and has also been a regional Channel 7 and 9 TV reporter with Prime7 and Win News.